Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study

The aim of this study was to evaluate the effects of a new antipsychotic compound on negative symptoms and cognitive deficit in schizophrenia. Psychiatric symptoms and cognition were assessed in 25 patients with schizophrenia, at baseline and after they had taken risperidone for 4 weeks. The Positive and Negative Symptoms Scale (PANSS), the Wisconsin Card Sorting Test (WCST) and two WAIS sub‐tests were used to assess the patients. After the study period, both negative and positive symptoms and also measures of cognitive performance improved significantly. The WCST results correlated with negative symptom scores before and after treatment. This suggests that negative symptoms and cognitive deficit have a common underlying substrate which is the target of the risperidone treatment. Our data show that risperidone may have a substantial effect on complex cognitive functions in schizophrenia, and they suggest that certain cognitive deficits are relatively dependent on the negative symptoms of this disorder.

[1]  H. Meltzer,et al.  The mechanism of action of novel antipsychotic drugs. , 1991, Schizophrenia bulletin.

[2]  H. Meltzer,et al.  The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs. , 1989, Psychopharmacology bulletin.

[3]  P. Anderer,et al.  Comparative Placebo-controlled Pharmacodynamic Studies with Zotepine and Clozapine Utilizing Pharmaco-EEG and Psychometry , 1987, Pharmacopsychiatry.

[4]  R. Kahn,et al.  The role of serotonin in schizophrenia. , 1988, Schizophrenia bulletin.

[5]  J. C. Stoof,et al.  Biochemical profile of risperidone, a new antipsychotic. , 1988, The Journal of pharmacology and experimental therapeutics.

[6]  J. Gerlach,et al.  New antipsychotics: classification, efficacy, and adverse effects. , 1991, Schizophrenia bulletin.

[7]  D. Pickar.  Prospects for pharmacotherapy of schizophrenia , 1995, The Lancet.

[8]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[9]  H. Meltzer,et al.  Effects of clozapine on cognitive function in schizophrenia. , 1994, The Journal of clinical psychiatry.

[10]  C J Niemegeers,et al.  Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. , 1988, The Journal of pharmacology and experimental therapeutics.

[11]  D. Owens.  The spectrum of depressive phenomena after spousal bereavement. , 1994 .

[12]  T. Goldberg,et al.  The Effect of Clozapine on Cognition and Psychiatric Symptoms in Patients with Schizophrenia , 1993, British Journal of Psychiatry.

[13]  D. Daniel.  Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders , 1994, Biological Psychiatry.

[14]  T. Goldberg,et al.  The effects of clozapine on neurocognition: an overview. , 1994, The Journal of clinical psychiatry.

[15]  L. Opler,et al.  Psychopharmacologic treatment of negative schizophrenic symptoms. , 1994, Comprehensive psychiatry.